Our Clinical Program
The BMTCT clinical program at St. Jude is a high-volume transplant and cellular therapy service that serves a diverse pediatric, adolescent and young adult patient population. We conduct approximately 100 transplants per year, consisting of both autologous and allogeneic donors, for a variety of malignant and non-malignant disease indications. BMTCT also provides a cellular therapy program, which includes the use of viral specific T-cells (VSTs), chimeric antigen receptor (CAR) engineered T-cells and gene therapy products.
Our inpatient and outpatient teams are fully staffed by advanced practice providers (NPs/PAs). We also provide multidisciplinary care for all of our patients. This includes routine incorporation of psychosocial, palliative care, pharmaceutical and infectious diseases experts into the patient’s daily care. Our team works with sub-specialists across a variety of disciplines and has a close partnership with St. Jude’s dedicated intensive care unit (ICU) and critical care specialists.
Learn more about the clinical BMTCT program at St. Jude.
Our Research Program
At St. Jude, the Division of BMTCT is an active research program. Our faculty consists of clinical and pre-clinical investigators. We collaborate across departments to develop novel therapeutic strategies with relevant biologic correlates. New protocols are routinely in development, and often stem directly from pre-clinical work generated by our faculty.
Learn more about our active clinical trials
Learn more about the Department of BMTCT
Fellowships are for one year. A fellowship can begin at any time, but a July 1 - June 30 schedule is preferred.
Our program trains physicians in the many aspects of the field of hematopoietic cell transplantation and cellular therapy. As a fellow, you will work directly with leaders in the field to further develop your knowledge base and clinical skills. Fellows will gain experience in areas involving:
- The indications for transplant, cellular and gene therapies
- Pre-therapy patient evaluation
- The identification and selection of hematopoietic cell sources, donor registries and methodologies of HLA typing
- Cell collection, manipulation and preservation procedures
- Production and administration of cell and gene therapy products
- The selection and administration of preparative regimens
- Management of patients receiving cellular and gene therapies
- The diagnosis and management of regimen related acute and long-term toxicities
Fellows are also regularly involved in clinical research and will have immense exposure to clinical trial design and implementation, as well as training in documentation and reporting for patients being treated on investigational trials.
We provide trainees with a strong clinical foundation, as well as personalize each fellow’s curriculum to their own career goals. A typical schedule includes:
- Weekly continuity clinic, which will consist of a variety of patients accrued over the course of the year
- Four months on inpatient service
- Four months on outpatient service
- Four months on electives and/or research with the option to focus on subspecialty areas such as:
- Immunophenotyping and HLA Laboratory
- Blood Bank/Blood Donor Room
- Human Applications laboratory (cell processing)
- Global Pediatric Medicine
- Palliative Care
- Infectious Diseases
BMTCT fellows will also participate in the Hematology/Oncology educational opportunities and will develop a clinical research project under close mentorship by a faculty member.
Applying for Fellowship
Eligible applicants will have completed a fellowship in pediatric hematology/oncology prior to BMTCT start date. International applicants must be ECFMG certified.
To learn more about current openings and the application process, please email Aimee Talleur, MD, Fellowship Program Director. A complete application will consist of: a curriculum vita (CV), personal statement, and three (3) letters of recommendation. Applicants may submit an application at any time. Our interview season is flexible, but typically occurs in the fall for a July 1 start.